Treatment of metastatic malignant melanoma with vemurafenib during pregnancy.

  title={Treatment of metastatic malignant melanoma with vemurafenib during pregnancy.},
  author={Aglaia Maleka and Gunilla Enblad and Gunnar Sj{\"o}rs and Anna Lindqvist and G Ullenhag},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  volume={31 11},
Introduction The prognosis of stage IV malignant melanoma (MM) has for decades remained poor with median survival of 6 to 9 months. Half of MM tumors carry an activating mutation of the proto-oncogene, B-RAF. The BRAF-inhibitor vemurafenib increases overall and progression-free survival compared with treatment with the chemotherapeutic agent dacarbazine in MM patients with advanced disease. Vemurafenib is since August 2011 approved by the US Food and Drug Administration and since January 2012… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 8 times over the past 90 days. VIEW TWEETS